Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2007; 28(03): 17-23
DOI: 10.1055/s-0041-1733223
Review

F-18 FDG PET/PET-CT in the Management of Lymphoma

Halanaik Dhanapathi
Department of Nuclear Medicine, AIIMS, New Delhi-110029, India
,
Rakesh Kumar
Department of Nuclear Medicine, AIIMS, New Delhi-110029, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
07 March 2022

© 2007. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Macapinlac HA. FDG PET and PET/CT imaging in lymphoma and melanoma. Cancer J. 2004;10:262-70.
  • 2 Blum RH, Seymour JF, Wirth A, MacManus M, Hicks RJ. Frequent impact of [18F] fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin’s lymphoma. Clin Lymphoma. 2003;4:43–49.
  • 3 Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18–2-fluoro-2- deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999;10:1185- 89.
  • 4 Joe A, Hoegerle S, Moser E. Cervical lymph node sarcoidosis as a pitfall in F-18 FDG positron emission tomography. Clin Nucl Med 2001;26:542-43.
  • 5 Taaleb K, Kaiser K, Wieler H. Elevated uptake of F- 18 FDG in PET scans in nonmalignant disease. Clin Nucl Med 2000;25:939-40
  • 6 Sandherr M, von Schilling C, Link T, et al. Pitfalls in imaging Hodgkin’s disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. Ann Oncol 2001;12:719-22.
  • 7 Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin’s disease and non- Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2003;30(Suppl 1):S42– 55.
  • 8 Stumpe KD, Urbielli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721-28.
  • 9 Hernandez-Maraver D,Hernandez-Navarro F, Gomez- Leon N, et al. Positron emission tomography/ computed tomography: diagnostic accuracy in lymphoma. Br J Haematol. 2006;135(3):293-302.
  • 10 Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro- D-glucose (FDG) PET in nodal staging. Radiology 1997;203:795-800.
  • 11 Cremerius U, Fabry U, Neuerburg J, et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 1998;19:1055-63.
  • 12 Talbot JN, Haioun C, Rain JD, et al. [18F]-FDG positron emission tomography in clinical management of lymphoma patients. Crit Rev Oncol Hematol 2001;38:193-21.
  • 13 Kumar R, Alavi A. Fluorodeoxyglucose-PET in the management of lymphoma. Radiol Clin North Am. 2004;42:1113-22.
  • 14 Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma: comparison with CT. Leuk Lymphoma. 2000; 39:543–53.
  • 15 Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer. 2004;91:850–54.
  • 16 Kumar R, Xiu Y, Potenta S, et al. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. J Nucl Med. 2004;45:1796-803.
  • 17 Cheson BD, Pfistner B, Juweid ME, et al. The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma Clin Oncol. 2007;10:25(5):579-86.
  • 18 Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Projectin Lymphoma.J Clin Oncol. 2007;10:25(5):571- 78.
  • 19 Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514–23.
  • 20 Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med. 2002;43:1018–27.
  • 21 Buchmann I, Neumaier B, Schreckenberger M, Reske S. [18F] 3’-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations—a pilot study. Cancer Biother Radiopharm. 2004;19:436–42.